AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8694154 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 231
Study 8694154 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 231
Study 1854570 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics plus enalapril or captopril (group 2)
Number of subjects: 34
Study 1854570 — intervention group
Group type: COMPARATOR
Intervention: Diuretics alone (group 1)
Number of subjects: 34
Study 6315227 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy (1‐(2‐chloroethyl‐3‐cyclohexyl‐1‐nitrosourea, cyclophosphamide, methotrexate, and vincristine followed by 4'‐demethylepipodophyllotoxin 9‐[4,6‐O‐(R) ethylidene‐beta‐D‐glucopyranoside] and doxorubicin at progression of disease)
Number of subjects: 146
Study 6315227 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (alternating the same drugs as continuous)
Number of subjects: 146
Study 30557331 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer image analysis using QCU‐CMS software
Number of subjects: 30
Study 30557331 — intervention group
Group type: COMPARATOR
Intervention: Visual classification by two independent readers
Number of subjects: 30
Study 26956618 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3 times per week (RT3, n=20)
Number of subjects: 52
Study 26956618 — intervention group
Group type: EXPERIMENTAL
Intervention: RT2 times per week (RT2, n=16)
Number of subjects: 52
Study 26956618 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=16)
Number of subjects: 52
Study 24576082 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 951
Study 24576082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair or poor satisfaction with primary care physician
Number of subjects: 951
Study 24576082 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having Medicaid
Number of subjects: 951
Study 24576082 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving a new assistive device in the past 6 months
Number of subjects: 951
Study 24576082 — intervention group
Group type: EXPERIMENTAL
Intervention: Staying in a nursing home in the past 6 months
Number of subjects: 951
Study 23046776 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) using neutral stimuli
Number of subjects: 2135
Study 23046776 — intervention group
Group type: COMPARATOR
Intervention: Attention Bias Modification (ABM) using positive stimuli
Number of subjects: 2135
Study 23046776 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) using threat stimuli
Number of subjects: 2135
Study 23046776 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) using appetitive stimuli
Number of subjects: 2135
Study 23046776 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 2135
Study 19409547 — intervention group
Group type: EXPERIMENTAL
Intervention: Müllerian inhibiting substance (MIS) assay
Number of subjects: 25
Study 18334054 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐day rush induction protocol
Number of subjects: 23
Study 18334054 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐day rush induction protocol
Number of subjects: 23
Study 18334054 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study 15759946 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Number of subjects: 16
Study 15759946 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Number of subjects: 16
Study 12019587 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual work
Number of subjects: 164
Study 12019587 — intervention group
Group type: COMPARATOR
Intervention: Nonmanual work
Number of subjects: 164
Study 10487369 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CHO-E)
Number of subjects: 6
Study 10487369 — intervention group
Group type: COMPARATOR
Intervention: Noncarbohydrate placebo (CON)
Number of subjects: 6
Study 7729608 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h clamped hyperglycemia (PG approximately 13.5 mmol/l)
Number of subjects: 15
Study 7729608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hyperglycemia (PG approximately 13.5 mmol/l)
Number of subjects: 15
Study 7729608 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (PG approximately 5 mmol/l)
Number of subjects: 15
Study 7729608 — intervention group
Group type: COMPARATOR
Intervention: 15 h of euglycemia (approximately 5 mmol/l)
Number of subjects: 15
Study 7729608 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 h of hyperglycemia (approximately 17 mmol/l)
Number of subjects: 15
Study 2117650 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 100 micrograms, four times a day
Number of subjects: 17
Study 2117650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7315500 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammary radiography screening
Number of subjects: 0
Study 7315500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (OD) PCI
Number of subjects: 449
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily (BD) PCI
Number of subjects: 449
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for patients treated with PCI
Number of subjects: 449
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross tumor volume (GTV)
Number of subjects: 449
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic GTV (tGTV)
Number of subjects: 449
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG performance score
Number of subjects: 449
Study 30292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay between end of chemotherapy and PCI
Number of subjects: 449
Study 29258763 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of intravenous dexamethasone and 1 dose of normal saline (Group B)
Number of subjects: 210
Study 29258763 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of intravenous dexamethasone (Group C)
Number of subjects: 210
Study 29258763 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of normal saline (Group A)
Number of subjects: 210
Study 26419487 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib alone
Number of subjects: 100
Study 26419487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin alone
Number of subjects: 100
Study 26419487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin and celecoxib combination
Number of subjects: 100
Study 26419487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25287827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib (combination therapy)
Number of subjects: 71
Study 22186564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing removed on postoperative day 1
Number of subjects: 70
Study 22186564 — intervention group
Group type: COMPARATOR
Intervention: Dressing removed on postoperative day 6
Number of subjects: 70
Study 20975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Group X (change from isoflurane to desflurane)
Number of subjects: 82
Study 20975764 — intervention group
Group type: COMPARATOR
Intervention: Group D (desflurane)
Number of subjects: 82
Study 20975764 — intervention group
Group type: COMPARATOR
Intervention: Group I (isoflurane)
Number of subjects: 82
Study 18349060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid (HR) subjects
Number of subjects: 16
Study 18349060 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid (EU) subjects
Number of subjects: 16
Study 15558608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (10% increase of baseline FiO2)
Number of subjects: 15
Study 15558608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (50% increase of ventilator cycling rate)
Number of subjects: 15
Study 15558608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hyperoxia and hyperventilation
Number of subjects: 15
Study 15558608 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver (control)
Number of subjects: 15
Study 14618041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bachmann's Bundle pacing
Number of subjects: 161
Study 14618041 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial pacing
Number of subjects: 161
Study 14618041 — intervention group
Group type: COMPARATOR
Intervention: Non-paced controls
Number of subjects: 161
Study 11998040 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-securing devices (specific devices not mentioned)
Number of subjects: 0
Study 11998040 — intervention group
Group type: COMPARATOR
Intervention: Traditional adhesive tape and pin device
Number of subjects: 0
Study 8933665 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-pertussis vaccines
Number of subjects: 0
Study 8933665 — intervention group
Group type: COMPARATOR
Intervention: Feasibility study assessments
Number of subjects: 0
Study 1540362 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.4 mg/kg)
Number of subjects: 36
Study 1540362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 36
Study 1540362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Labetalol and Placebo)
Number of subjects: 36
Study 3546255 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral meclofenamate during the follicular phase
Number of subjects: 32
Study 3546255 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral meclofenamate during the luteal phase
Number of subjects: 32
Study 3546255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) during the luteal phase
Number of subjects: 32
Study 3546255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg inhaled metaproterenol
Number of subjects: 32
Study 3546255 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 32
Study 30883057 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 552
Study 30883057 — intervention group
Group type: COMPARATOR
Intervention: Delayed coronary angiography
Number of subjects: 552
Study 29966858 — intervention group
Group type: COMPARATOR
Intervention: Response inhibition training using Go/No-go task, Stop Signal Task, and Collision Detection Task over five days.
Number of subjects: 65
Study 29966858 — intervention group
Group type: COMPARATOR
Intervention: Enhanced response inhibition training using Go/No-go and SST tasks with clearer performance feedback over 10 days.
Number of subjects: 65
Study 26813208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2400 IU/d)
Number of subjects: 623
Study 26813208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 24355993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 100
Study 24355993 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional balance training
Number of subjects: 100
Study 24355993 — intervention group
Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 100
Study 23174048 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES facial device (20 min/day, 5 days/week)
Number of subjects: 108
Study 23174048 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 108
Study 20078609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxentan 100 mg daily for 7 days
Number of subjects: 24
Study 20078609 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 24
Study 20078609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxentan 100 mg
Number of subjects: 24
Study 20078609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17686882 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E(2)) administration
Number of subjects: 0
Study 17686882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (pure antiestrogen)
Number of subjects: 0
Study 17686882 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/GHRP-2 stimulation
Number of subjects: 0
Study 17686882 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E(2))
Number of subjects: 0
Study 17686882 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH stimulation
Number of subjects: 0
Study 16254541 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (promoting condoms and vaginal microbicides)
Number of subjects: 427
Study 16254541 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (promoting condoms and vaginal microbicides)
Number of subjects: 427
Study 16254541 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfect condom use (regardless of intervention arm)
Number of subjects: 427
Study 16254541 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a vaginal microbicide during > or =50% of acts of intercourse
Number of subjects: 427
Study 11902371 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Intake Recording Software System (FIRSSt)
Number of subjects: 138
Study 11902371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-conducted 24-hour dietary recall (24hDR)
Number of subjects: 138
Study 11902371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair sample as a bogus pipeline
Number of subjects: 138
Study 11902371 — intervention group
Group type: COMPARATOR
Intervention: Observation of school lunch
Number of subjects: 138
Study 10580458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5, 25, or 50 mg/d)
Number of subjects: 5435
Study 10580458 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, diclofenac, nabumetone)
Number of subjects: 5435
Study 7825523 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation (12 g fish oil)
Number of subjects: 9
Study 7825523 — intervention group
Group type: COMPARATOR
Intervention: Corn plus olive oil (control)
Number of subjects: 9
Study 2328299 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem conventional tablet (2 x 30 mg)
Number of subjects: 24
Study 2328299 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem slow-release capsule (120 mg SR)
Number of subjects: 24
Study 438650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acid mixture (cholic‐chenodeoxycholic 2:1, 20 mg/kg)
Number of subjects: 4
Study 438650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitosterol-bile acid mixture (bile acid mixture plus sitosterols, 200 mg/kg)
Number of subjects: 4
Study 438650 — intervention group
Group type: COMPARATOR
Intervention: Control (pretreatment)
Number of subjects: 4
Study 31837988 — intervention group
Group type: EXPERIMENTAL
Intervention: IC/IS + HR-cervix
Number of subjects: 46
Study 31837988 — intervention group
Group type: COMPARATOR
Intervention: IC/IS
Number of subjects: 46
Study 31045402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically based family therapy (EBFT)
Number of subjects: 183
Study 31045402 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 183
Study 28453843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 184
Study 25887789 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective laparoscopic appendectomy plus maintenance treatment (5‐ASA)
Number of subjects: 0
Study 25887789 — intervention group
Group type: COMPARATOR
Intervention: Maintenance 5‐ASA treatment (no appendectomy)
Number of subjects: 0
Study 24462523 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS normalization in leads V1 and V2 (n = 66 [18%])
Number of subjects: 375
Study 24462523 — intervention group
Group type: EXPERIMENTAL
Intervention: New or increased R wave in leads V1‐V2 (n = 267 [71%])
Number of subjects: 375
Study 24462523 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS difference ≤ ‐25 ms
Number of subjects: 375
Study 24462523 — intervention group
Group type: EXPERIMENTAL
Intervention: Good substrate (low to moderate QRS score and LV activation time ≥110 ms)
Number of subjects: 375
Study 24462523 — intervention group
Group type: COMPARATOR
Intervention: Poor substrate and persistent LBBB QRS complex (absent BV fusion; QRS type 3: n = 42 [11%])
Number of subjects: 375
Study 24462523 — intervention group
Group type: EXPERIMENTAL
Intervention: Best BV QRS fusion pattern and greater reduction in electrical asynchrony (larger QRS difference)
Number of subjects: 375
Study 22272985 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Pedometer (GP)
Number of subjects: 40
Study 22272985 — intervention group
Group type: COMPARATOR
Intervention: Group Booklet (GB)
Number of subjects: 40
Study 19338149 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Liangxue Compound (SLC)
Number of subjects: 73
Study 19338149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 17460329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior low-intensity exercise (E)
Number of subjects: 14
Study 17460329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta meal
Number of subjects: 14
Study 17460329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread meal
Number of subjects: 14
Study 17460329 — intervention group
Group type: COMPARATOR
Intervention: No prior low-intensity exercise (NE)
Number of subjects: 14
Study 15099874 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical termination of pregnancy with continuous ultrasound guidance
Number of subjects: 230
Study 12492462 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD)
Number of subjects: 31
Study 9618624 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 152
Study 9618624 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforcement intervention
Number of subjects: 152
Study 9618624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 7730009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing model implemented on Ward X (experimental ward)
Number of subjects: 0
Study 7730009 — intervention group
Group type: COMPARATOR
Intervention: Control ward (Ward Y)
Number of subjects: 0
Study 2497647 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 cm capsule (12 mg of levonorgestrel)
Number of subjects: 48
Study 2497647 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 cm capsule (21.6 mg of levonorgestrel)
Number of subjects: 48
Study 7293937 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs (0.5 cup, approximately 500 mg cholesterol)
Number of subjects: 16
Study 7293937 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-free egg substitute
Number of subjects: 16
Study 31606815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with arthroplasty (ACDA)
Number of subjects: 0
Study 31606815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with intervertebral cage (ACDF)
Number of subjects: 0
Study 31606815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without intervertebral cage (ACD)
Number of subjects: 0
Study 31606815 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical methods
Number of subjects: 0
Study 30602311 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical spironolactone
Number of subjects: 17
Study 30602311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28880750 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua-Lymphatic Therapy (ALT), group sessions twice a week for 6 weeks
Number of subjects: 57
Study 28880750 — intervention group
Group type: COMPARATOR
Intervention: Control group, group sessions twice a week for 6 weeks
Number of subjects: 57
Study 25541155 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment
Number of subjects: 1031
Study 25541155 — intervention group
Group type: COMPARATOR
Intervention: No PN (initially)
Number of subjects: 1031
Study 25541155 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent PN
Number of subjects: 1031
Study 25541155 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >55, maximum grade of PN during docetaxel treatment, persistent muscle and joint pain, stomatitis, fatigue
Number of subjects: 1031
Study 24081023 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg/week
Number of subjects: 24
Study 24081023 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day
Number of subjects: 24
Study 24081023 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 pts with PHPT, no surgery indications)
Number of subjects: 24
Study 21267745 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat + O(3) (31°C + 70% rh + 0.10 ppm O(3))
Number of subjects: 10
Study 21267745 — intervention group
Group type: COMPARATOR
Intervention: Control (20°C + 50% rh)
Number of subjects: 10
Study 21267745 — intervention group
Group type: COMPARATOR
Intervention: Control + O(3) (20°C + 50% rh + 0.10 ppm O(3))
Number of subjects: 10
Study 21267745 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat (31°C + 70% rh)
Number of subjects: 10
Study 19122354 — intervention group
Group type: COMPARATOR
Intervention: 1 mg overnight dexamethasone suppression test
Number of subjects: 100
Study 19122354 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg overnight dexamethasone suppression test
Number of subjects: 100
Study 18082216 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin)
Number of subjects: 0
Study 18082216 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride (0.5 mg)
Number of subjects: 0
Study 18082216 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0
Study 15154366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nagipol (biologically active additive based on beer yeasts)
Number of subjects: 0
Study 12364431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Medroxyprogesterone Acetate (MPA)
Number of subjects: 28
Study 12364431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone (MP)
Number of subjects: 28
Study 12364431 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Micronized Progesterone (MP)
Number of subjects: 28